Home > Insider Trading > Filing (0001209191-18-052791)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1724344	Entasis Therapeutics Holdings Inc.	ETTX	()	G7

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1388325	A/S Holdings Novo	Tuborg Havnevej 19 Hellerup G7 2900		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-09-28	1,092,008	$0.00	1,092,008	No	4	C	Direct
Common Stock	Acquisiton	2018-09-28	1,089,835	$15.00	2,181,843	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2018-09-28	7,000,000	$0.00	337,707	$0.00
Common Stock	Series B-1 Preferred Stock	Disposition	2018-09-28	14,237,288	$0.00	686,861	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct
0			No	4	C	Direct

Footnotes

Series B and B-1 redeemable convertible preferred stock (collectively, the "Preferred Stock") has no expiration date and is convertible at any time, at the holder's election. Upon the closing of the Issuer's initial public offering, the Preferred Stock automatically converted into shares of the Issuer's Common Stock based on the Series B Preferred Stock Conversion Price, Series B-1 Tranche A Preferred Stock Conversion Price and Series B-1 Tranche B Preferred Stock Conversion Price (each as defined in the Issuer's Amended and Restated Certificate of Incorporation).
Includes 67,440 shares of common stock issued per dividends accrued through September 27, 2018.
Represents a purchase from the underwriters in the Issuer's initial public offering.